V937 for Neoplasm Metastasis
This study is evaluating whether a combination of two drugs may help treat cancer.
See full descriptionAbout the trial for Neoplasm Metastasis
Treatment Groups
This trial involves 8 different treatments. V937 is the primary treatment being studied. Participants will be divided into 8 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Neoplasm Metastasis. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether V937 will improve 4 primary outcomes and 9 secondary outcomes in patients with Neoplasm Metastasis. Measurement will happen over the course of Up to approximately 4 weeks.
Patient Q & A Section
What is neoplasm metastasis?
Neoplasm metastasis is the establishment of distant tumors by cancer cells from one neoplasm that have escaped primary tumor control. The exact pathogenesis of neoplasm metastasis has still not been fully understood. The development of new agents to prevent metastasis, and agents to treat metastatic tumor sites are discussed.
What are the signs of neoplasm metastasis?
The following symptoms may be considered as suggestive signs of impending neoplasmal metastasis; pain in the bones, joints or other parts of the body; coughing up blood; and swollen lymph nodes in the axillary, inguinal, and groin areas.
How many people get neoplasm metastasis a year in the United States?
A significant percentage of the population presents with metastatic neoplasm, with a high percentage of malignant tumors in different regions of the body. The number of people who get neoplasm metastasis is greater for the southern and eastern regions of the United States.
What causes neoplasm metastasis?
The cause of neoplasm metastasis is still uncertain. But it could be associated with genetic, immunological, and inflammatory factors. Neoplasm metastasis also is related to metastasis of primary tumors, which occur in the same person.
What are common treatments for neoplasm metastasis?
When neoplasms are metastasized to the thoracic, abdominal, or pelvic viscera, chemotherapy is always used, but chemotherapy is not always used to treat the neoplasm. Local irradiation can be employed in certain cases. For patients who have bone, bone marrow or liver metastases, palliative treatment is more frequent than treatment to eradicate metastases by surgery.
Can neoplasm metastasis be cured?
The current study was able to show that metastastic lesions can be eliminated, even after metastasis. However, metastatic lesions were found to be resistant to a chemotherapy using vincristine and doxorubicin for at least a month.
What is the latest research for neoplasm metastasis?
The incidence of metastasis is increasing. However, prognosis remains poor. Most metastatic neoplasms are hormone-sensitive cancers such as breast carcinoma, prostate carcinoma, and gonadal carcinoma. More efforts are needed in the advancement of gene therapy. The application of chemotherapeutic drugs in combination with gene therapy should be encouraged. In addition, more randomized clinical controlled trials are indispensable and should be performed to improve the prognosis of metastatic neoplasm.
Who should consider clinical trials for neoplasm metastasis?
Neoplasm metastasis trials (and other rare cancers) are under-represented in the literature. As such, clinicians faced with metastatic solid tumors need to consider treatment options based on the most up-to-date information and, more importantly, understand the risks and benefits of the specific treatment options available to them.
Has v937 proven to be more effective than a placebo?
The use of PEP-S was found to be more effective than a placebo for the treatment of recurrent vulvar cancer. The use of PEP-S should be considered in recurrent vulvar premalignancy and dysplasia patients with vulvar neoplasms. PEP-S is effective in reducing lesions of the vaginal vault with histologic evidence of residual disease and neoplastic keratinization of the intraepithelial lining of the vagina. The use of PEP-S should be considered in all women with a history of recurrent vulvar malignancies.
Does neoplasm metastasis run in families?
Based on the results of this large-scale, multi-center study, no significant differences in metastasis occurrence in non-familial and familial neoplasm cases were found. Thus the results of our study do not support any influence of the familial on the occurrence of neoplasm metastasis.
What does v937 usually treat?
The study reported here gives an overview on the current status of therapeutic intervention against v937. The data also illustrates the need to standardize the diagnostic criteria as well as the definition of 'effective/therapeutic concentration' in future trials in order to avoid a large array of different conclusions.
What is the survival rate for neoplasm metastasis?
Survival rates of metastatic disease are dependent on a patient's initial tumor type, stage, and treatment regimen. Metastases from many types of primary tumors have a very high survival rate, and they can become malignant, albeit rarely. The median prognoses for [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer), colorectal cancer, and oesophageal cancer are around five to seven years, whereas those for other types are typically less than two years.